SPECIALTY GUIDELINE MANAGEMENT

FOLOTYN (pralatrexate) pralatrexate

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)

B. Compendial Uses

- 1. Adult T-cell leukemia/lymphoma (ATLL)
- 2. Mycosis fungoides/Sezary syndrome (MF/SS)
- 3. Cutaneous anaplastic large cell lymphoma (ALCL)
- 4. Extranodal NK/T-cell lymphoma
- 5. Hepatosplenic T-cell lymphoma
- 6. Anaplastic large cell lymphoma
- 7. Peripheral T-cell lymphoma not otherwise specified
- 8. Angioimmunoblastic T-cell lymphoma
- 9. Enteropathy associated T-cell lymphoma
- 10. Monomorphic epitheliotropic intestinal T-cell lymphoma
- 11. Nodal peripheral T-cell lymphoma with TFH phenotype
- 12. Follicular T-cell lymphoma
- 13. Breast implant associated anaplastic large cell lymphoma (ALCL)

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

A. Peripheral T-cell lymphoma (PTCL)

Authorization of 12 months may be granted for treatment of PTCL (including the following subtypes: anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, or follicular T-cell lymphoma) when both of the following criteria are met:

- 1. The requested medication will be used as a single agent.
- 2. The requested medication will be used to treat relapsed or refractory disease or for initial palliative therapy.

B. Adult T-cell leukemia/lymphoma (ATLL)

Authorization of 12 months may be granted for treatment of ATLL when both of the following criteria are met:

pralatrexate-Folotyn 1702-A SGM P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



- 1. The requested medication is used as a single agent.
- 2. The requested medication is used as subsequent therapy.

C. Mycosis fungoides/Sezary syndrome (MF/SS)

Authorization of 12 months may be granted for treatment of MF or SS.

D. Cutaneous anaplastic large cell lymphoma

Authorization of 12 months may be granted for treatment of cutaneous anaplastic large cell lymphoma (ALCL) when the requested medication is used as a single agent.

E. Extranodal NK/T-cell lymphoma

Authorization of 12 months may be granted for treatment of extranodal NK/T-cell lymphoma when all of the following criteria are met:

- 1. The requested medication will be used as a single agent.
- 2. The member has relapsed or refractory disease.
- 3. The member has had an inadequate response or contraindication to asparaginase-based therapy (e.g., pegaspargase).

F. Hepatosplenic T-cell lymphoma

Authorization of 12 months may be granted for treatment of hepatosplenic T-cell lymphoma when both of the following criteria are met:

- 1. The requested medication will be used as a single agent.
- 2. The member has had two or more previous lines of chemotherapy.

G. Breast implant-associated anaplastic large cell lymphoma (ALCL)

Authorization of 12 months may be granted for treatment of breast implant associated ALCL when both of the following criteria are met:


- 1. The requested medication will be used as a single agent.
- 2. The requested medication will be used as subsequent therapy.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

IV. REFERENCES

- 1. Folotyn [package insert]. East Windsor, NJ: Acrotech Biopharma LLC; September 2020.
- 2. Pralatrexate [package insert]. Lake Zurich, IL: Fresenius Kabi; September 2022.
- 3. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed April 5, 2024.



© 2024 CVS Caremark. All rights reserved.

